ライフサイエンスコーパス: pulmonary function

1 roup performance status of 0-2, and adequate pulmonary function.

2 n single nucleotide polymorphisms (SNPs) and pulmonary function.

3 included questionnaires, blood samples, and pulmonary function.

4 onally overlapped with those associated with pulmonary function.

5 e tested whether Htr4-null mice have altered pulmonary function.

6 ng exhaled nitric oxide, total serum IgE and pulmonary function.

7 ssive pulmonary fibrosis leading to impaired pulmonary function.

8 f nicotine on lung development and offspring pulmonary function.

9 onal responses, including cardiovascular and pulmonary function.

10 ients with elevated IgE levels and decreased pulmonary function.

11 pregnancy demonstrate lifelong decreases in pulmonary function.

12 monary function whereas the other had stable pulmonary function.

13 w, moderate, high), the allergic status, and pulmonary function.

14 errelation between vitamin D, adiposity, and pulmonary function.

15 lting in alveolar simplification and reduced pulmonary function.

16 inhibited collagen deposition and preserved pulmonary function.

17 e since the early 1990 for the assessment of pulmonary function.

18 improvement in developmental milestones and pulmonary function.

19 e was not associated with adverse effects on pulmonary function.

20 phy mosaic pattern consistent with sustained pulmonary function.

21 thrombocytosis, elevated VEGF, and abnormal pulmonary function.

22 , there are limits in the current testing of pulmonary function.

23 econdary RSV infection and improve long-term pulmonary function.

24 study with any adverse change in cardiac or pulmonary function.

25 mal reference standards in the prediction of pulmonary function.

26 his is associated with changes in cardiac or pulmonary function.

27 e outcomes and without measurable changes in pulmonary function.

28 of current or former smokers with preserved pulmonary function.

29 make conclusions about the impact of IL33 on pulmonary function.

30 nd/or nerve function, physical function, and pulmonary function.

31 blood from 14 asthmatic patients with normal pulmonary function, 14 patients with COA, 11 patients in

32 of patients' arm anthropometrics, strength, pulmonary function, 6-minute-walk distance, and cognitiv

33 outcomes was highest for pulmonary (abnormal pulmonary function, 65.2% [95% CI, 60.4%-69.8%]), audito

34 e prevalence of asthma diagnosis and related pulmonary function abnormalities in an HIV-infected coho

35 5 years later, whereas exercise capacity and pulmonary function abnormalities were associated only wi

36 tematically evaluate changes in symptoms and pulmonary function after acute selective NSAID or COX-2

37 greater rate in lobectomy patients with poor pulmonary function after thoracotomy compared with VATS.

38 Pulmonary function and adverse event frequency did not c

39 egrating pathway-based methods with GWASs of pulmonary function and airflow obstruction would identif

40 N29 and KIM-127, is associated with impaired pulmonary function and airway eosinophilia, respectively

41 ing GWAS single-nucleotide polymorphisms for pulmonary function and analyzed associations with FEV1/F

42 IA) study and evaluated the relation between pulmonary function and ancestry by means of linear regre

43 We showed previously that pulmonary function and arterial oxygen saturation in NY1

44 Pulmonary function and asthma control measures generally

45 tion marker CD203c inversely correlated with pulmonary function and body mass index in A fumigatus-se

46 ulmonary aspergillosis (ABPA), which affects pulmonary function and clinical outcomes.

47 ay inflammation induced by house dust mites, pulmonary function and cytokine profiles in Htr4-null mi

48 the impact of maternal smoking on offspring pulmonary function and decrease the incidence of wheeze

49 t destroyed sections of the lung can improve pulmonary function and exercise capacity but its benefit

50 chial-valve treatment significantly improved pulmonary function and exercise capacity in patients wit

51 The relationships between pulmonary function and imaging measurements were determi

52 lung development, with lifelong decreases in pulmonary function and increased asthma risk.

53 ght into the molecular mechanisms regulating pulmonary function and into molecular targets for future

54 ulopathy, and in animal models, ERAs improve pulmonary function and ischemic-reperfusion injury in lu

55 hoalveolar lavage fluid that correlated with pulmonary function and nitric oxide levels, whereas HC-H

56 d consent, 51 healthy volunteers with normal pulmonary function and no history of smoking were imaged

57 unt for individual age-based trajectories of pulmonary function and other covariates including tobacc

58 ne-mediated senescent cell ablation improves pulmonary function and physical health, although lung fi

59 n SCD mice is sufficient to improve baseline pulmonary function and prevent hypoxia-reoxygenation-ind

60 mSSPN overexpression improved pulmonary function and reduced dystrophic histopathology

61 en cGVHD model, ibrutinib treatment restored pulmonary function and reduced germinal center reactions

62 exploring the effects of poisonous gases on pulmonary function and related problems.

63 de airway clearance, regular surveillance of pulmonary function and respiratory microbiology, and use

64 e effects of smoking in pregnancy on newborn pulmonary function and respiratory morbidities.

65 beginning one month post-transplant restored pulmonary function and reversed lung fibrosis, which was

66 al study collecting repeated measurements of pulmonary function and smoking over 20 years (March 26,

67 e the association between plasma 25(OH)D and pulmonary function and the effect modifications of sex a

68 to determine the effect of these clusters on pulmonary function and treatment response to inhaled ant

69 nonuclear cells (PBMCs) with the outcomes of pulmonary functions and overall survival, and used the m

70 e-operative evaluation of cardiovascular and pulmonary functions and post-operative fluid management

71 The results of pulmonary-function and cardiopulmonary-exercise testing

72 ith an exacerbated immune response, impaired pulmonary function, and altered lung histology.

73 ologic (total and A fumigatus-specific IgE), pulmonary function, and body mass index measurements wer

74 s; peripheral arterial endothelial function, pulmonary function, and coronary artery calcium were ass

75 between baseline biological, asthma control, pulmonary function, and demographic markers and responsi

76 ased lung inflammation, disrupted rhythms of pulmonary function, and emphysema.

77 itial lung disease meeting defined dyspnoea, pulmonary function, and high-resolution CT (HRCT) criter

78 a Zubrod performance status of 0-1, adequate pulmonary function, and no evidence of supraclavicular o

79 thy subjects, asthmatic patients with normal pulmonary function, and patients with COA were determine

80 current or former smokers who had preserved pulmonary function as assessed by spirometry (FEV1:FVC >

81 randomized to placebo (n = 83), had improved pulmonary function as measured by TPTEF:TE (0.383 vs 0.3

82 seline, and post-bronchodilator-administered pulmonary function assessed during follow-up.

83 tissue motion analyses, to achieve regional pulmonary function assessment in beta-ENaC-overexpressin

84 an diagnosis of asthma/EIB were referred for pulmonary function assessment.

85 Changes from baseline in pulmonary function at Week 48 were analyzed by emphysema

86 None of the patients with declining pulmonary function attained the ability to hop or run; t

87 of asthma control (symptoms, rescue therapy, pulmonary function), based on exhaled nitric oxide, or o

88 udy, and was further confirmed with COPD and pulmonary function-based family analyses, respectively.

89 For pulmonary function-based screening tools, FEV1/FEV6 was

90 Asthma outcomes included pulmonary function, bronchial reactivity, asthma symptom

91 nal wheezing phenotypes, and measurements of pulmonary function, bronchial responsiveness, and atopy)

92 r(R) is a suitable DPI for patients with low pulmonary function but patients should be alert to avoid

93 ated traits in genome-wide studies including pulmonary function, cancers, inflammatory diseases, and

94 e emphysema and fibrosis extents, as well as pulmonary function changes, over 48 weeks.

95 d with inducible STAT3-deficient T cells had pulmonary function comparable to the healthy negative co

96 e and acute bronchial obstruction to improve pulmonary function compared to injured animals without t

97 Seven healthy volunteers with normal pulmonary function completed the study with evaluable da

98 Brachial artery endothelial function, pulmonary function, coronary artery calcium, and carotid

99 th systemic inflammatory markers and reduced pulmonary function, correlated with expression of genes

100 The relationship between pulmonary function data and CT densitometric changes in

101 0 Latino children (8-21y) with genotypic and pulmonary function data from the GALA II cohort.

102 the association between ILA progression and pulmonary function decline (and mortality).

103 tudy is associated with an increased rate of pulmonary function decline and increased risk of death.

104 lymorphism (SNP) in the CHRNA5/3/B4 locus on pulmonary function decline as mediated by cigarette smok

105 Pulmonary function decline is a major contributor to mor

106 ate markers have been explored, ranging from pulmonary function decline to biomarkers.

107 a role of CDC42 in the TH1 polarization and pulmonary function deficits found in patients with obesi

108 opic TH1-polarized systemic inflammation and pulmonary function deficits found in patients with pedia

109 response, with exacerbated IRIS and greater pulmonary function deficits than those in RAG2 and RAG/I

110 d systemic inflammation that correlates with pulmonary function deficits, but the pathways underlying

111 Daily oscillations of pulmonary function depend on the rhythmic activity of th

112 the mitral annulus [E']; P = .003), impaired pulmonary function (diffusing capacity of lungs for carb

113 function, assessed by annual brain imaging, pulmonary function, echocardiographic image, and laborat

114 None of the exploratory pulmonary function end points were statistically signifi

115 Exploratory outcomes included additional pulmonary function end points, pulmonary exacerbations,

116 cts of antacid therapy use from baseline for pulmonary function, exercise tolerance, survival, hospit

117 not seem to underlie GWAS associations with pulmonary function for common variants in ADAM19 and HTR

118 tion early in life is associated with better pulmonary function for patients with cystic fibrosis (CF

119 erum 25-hydroxyvitamin D (25-OHD) levels and pulmonary function (forced expiratory volume in 1 sec [F

120 We also compared how pulmonary function, frequency of asthma exacerbations, a

121 Pulmonary function, gas exchange, and invasive hemodynam

122 Impaired pulmonary function, greater healthcare utilization, and

123 nonimpaired measures of muscle strength and pulmonary function had significantly slower 4-m gait spe

124 tic current or former smokers with preserved pulmonary function have exacerbations, activity limitati

125 onship between genetic variation in HTR4 and pulmonary function identified in human GWAS.

126 8 of 30 patients with or without significant pulmonary function impairment.

127 dyspnea, health-related quality of life, and pulmonary function in a cohort of 2,416 people who smoke

128 nvestigate whether neonatal hyperoxia alters pulmonary function in aging mice.

129 LS patients, suggesting that PEA can enhance pulmonary function in ALS.

130 There was no improvement noted in pulmonary function in animals that received a higher dos

131 variants, we studied the natural history of pulmonary function in correlation to motor abilities in

132 ted whether differences exist in spirometric pulmonary function in healthy children across the Indian

133 tonin) receptor 4 (HTR4) are associated with pulmonary function in human GWASs.

134 g association (combined P < 5 x 10(-8)) with pulmonary function in or near MFAP2, TGFB2, HDAC4, RARB,

135 RXFP1 expression is directly associated with pulmonary function in patients with IPF.

136 ed an easily applied formula for determining pulmonary function in patients with SSc that identifies

137 We prospectively assessed cardiac and pulmonary function in patients with stable coronary arte

138 loablative autologous HSCT improves skin and pulmonary function in patients with systemic sclerosis f

139 increased occurrence of cough and change in pulmonary function in the group receiving inhaled insuli

140 feature alterations occurred with worsening pulmonary function independent of an increase in disease

141 nificantly different from NRA with regard to pulmonary function indices, bronchial basement membrane

142 expression in the lung, locomotor activity, pulmonary function, inflammatory, pro-fibrotic and emphy

143 ates that nsv823469 plays a role in COPD and pulmonary function inheritance by potentially altering e

144 Obesity-related reduction in pulmonary function is a possible mechanism in the pathwa

145 Association of monocyte activation with pulmonary function is mediated by body mass index, where

146 ut whether it has similar adverse effects on pulmonary function is unclear.

147 cine: the growth of intensive care units and pulmonary function laboratories and the advent of fibero

148 ng principles by equipment manufacturers and pulmonary function laboratories can improve the interpre

149 ciety committee on Proficiency Standards for Pulmonary Function Laboratories has recognized the need

150 some 4q31 have been strongly associated with pulmonary function levels and moderate-to-severe chronic

151 itrogen dioxide levels) were associated with pulmonary function levels below 85% of those predicted f

152 op chronic obstructive pulmonary disease and pulmonary function levels, including the forced expirato

153 Pulmonary function measurement, bronchoscopy, laboratory

154 ned to provide recommendations on the use of pulmonary function measures as asthma outcomes that shou

155 interleukin-6; miR-1180 was associated with pulmonary function measures at a marginally significant

156 The pulmonary function measures of forced expiratory volume

157 Pulmonary function measures reflect respiratory health a

158 All measures considered for pulmonary function met consensus criteria for exclusion.

159 ndary outcomes included histamine challenge, pulmonary function, mini-asthma quality of life question

160 No patient has developed worsening pulmonary function or acute or chronic rejection.

161 nships between beta1-integrin activation and pulmonary function or eosinophil-bound P-selectin in sub

162 differences were noted in early measures of pulmonary function or in immunologic or coagulation stat

163 y meaningful improvements in asthma control, pulmonary function, or exacerbations in patients with se

164 admission, no differences in comorbidities, pulmonary function, or median sequential organ failure a

165 tions with transient early wheezing, reduced pulmonary function, or nonasthma phenotypes.

166 (chronic bronchitis, asthma, other abnormal pulmonary function, other respiratory disease), and mult

167 ted with carbon monoxide diffusion capacity, pulmonary function outcomes, and overall survival.

168 ography at Year 25 of CARDIA and measures of pulmonary function over 20 years in 3,000 participants.

169 001), as well as longitudinal differences in pulmonary function (P < .0001).

170 unction, cognition, mental health, survival, pulmonary function, pain, and muscle and/or nerve functi

171 aseline and 6 weeks in any of the cardiac or pulmonary function parameters.

172 ctomy over lobectomy via thoracotomy in poor pulmonary function patients [FEV1 (forced expiratory vol

173 Pulmonary function patterns were categorized based on th

174 ctive (HR 1.31; 95% CI: 0.64-2.32; P = .557) pulmonary function patterns were not associated with ear

175 Poor pulmonary function predicts respiratory complications re

176 This study demonstrates that pulmonary function profiles can be used in combination w

177 sed survival, extreme weight loss, decreased pulmonary function, pulmonary haemorrhage and pathologic

178 tly with disease severity and inversely with pulmonary function, quality of life, and prognosis.

179 e primary outcome was measurement of newborn pulmonary function (ratio of the time to peak tidal expi

180 tal capacity (FVC), a spirometric measure of pulmonary function, reflects lung volume and is used to

181 phenotypes, we demonstrated that stroke and pulmonary function show enrichment for smoking-related g

182 data on respiratory symptoms and diagnoses, pulmonary function, sputum cell counts, and asthma-relat

183 tomography (CT) scans of the chest, resting pulmonary function studies (spirometry and/or plethysmog

184 Pulmonary function studies performed in 739 patients sho

185 tudy subjects, which included laboratory and pulmonary function studies, chest computed tomography, a

186 th and largely preserved cardiometabolic and pulmonary functions suggest the potential for near-full

187 tomography (CT) metrics on a lobar basis and pulmonary function test (PFT) results on a whole-lung ba

188 sing spondylitis (AS) and compared them with pulmonary function test (PFT) results, demographic chara

189 sometimes in individuals without symptoms or pulmonary function test abnormalities.

190 ell Disease, was constructed using the first pulmonary function test at >21 years of age.

191 An obstructive pattern in pulmonary function test is common after lung transplanta

192 During an asthma exacerbation, pulmonary function test parameters (PFTs) return to thei

193 available in the United States; if baseline pulmonary function test results are normal to near norma

194 Pulmonary function test results before and after ARS rev

195 malignancy, and had available pretransplant pulmonary function test results.

196 est, exercise), PaO2, hemoglobin, or resting pulmonary function test results.

197 evelop a new Technical Standard on reporting pulmonary function test results.

198 A pulmonary function test was performed measuring prebronc

199 .5 (range, 21.0-67.8) years at time of first pulmonary function test, and a median follow-up of 5.5 y

200 >/=10% decline in FEV1 relative to the prior pulmonary function test, are subsequently at increased r

201 f asthma and/or EIB were required to undergo pulmonary function testing (PFT) to permit the use of in

202 Respiratory muscle function was assessed by pulmonary function testing (PFT).

203 comitant symptoms, the physical examination, pulmonary function testing and arterial blood gas analys

204 ysis of variance, and the relationships with pulmonary function testing and eosinophil counts were as

205 dditional research about the roles of infant pulmonary function testing and food avoidance or dietary

206 To review the recent literature related to pulmonary function testing and how it relates to the pre

207 univariable and multivariable analyses with pulmonary function testing and quality of life survey da

208 nt Gal-3 assessment using plasma samples and pulmonary function testing between 1995 and 1998.

209 thy lungs and are related to measurements of pulmonary function testing but not to eosinophil level.

210 ant linear correlations with measurements of pulmonary function testing but not with eosinophil level

211 Pulmonary function testing can be used to quantify lung

212 Postoperative pulmonary function testing has shown significant improve

213 ing questionnaires or office-based screening pulmonary function testing or to determine the benefits

214 Infant pulmonary function testing performed as an exploratory o

215 Pulmonary function testing revealed no significant diffe

216 Pulmonary function testing reveals an obstructive ventil

217 Pulmonary function testing was performed according to gu

218 high-resolution computed tomography, infant pulmonary function testing, bronchoscopy with bronchoalv

219 ubjects underwent sputum and blood analyses, pulmonary function testing, exercise tolerance, and qual

220 as performed using questionnaires, atopy and pulmonary function testing, exhaled nitric oxide measure

221 ective standardized evaluation included full pulmonary function testing, high-resolution chest tomogr

222 and, according to their symptoms, underwent pulmonary function testing, methacholine challenge, spec

223 the patients were correlated with results of pulmonary function testing.

224 A diagnosis of asthma was confirmed by pulmonary function testing.

225 , serum ferritin (iron overload, 24.0%), and pulmonary function testing/chest x-ray (pulmonary dysfun

226 Data on cardiopulmonary-exercise and pulmonary-function testing were compared with data obtai

227 and exposure history, physical examination, pulmonary-function testing, and high-resolution computed

228 ent's global assessment of disease activity, pulmonary function tests (forced vital capacity, diffusi

229 t forced expiratory flows and volumes infant pulmonary function tests (iPFTs) were measured in 44 inf

230 duration of illness, laboratory results and pulmonary function tests (PFT).

231 Pulmonary function tests (PFTs) are routinely used to as

232 erogeneity is greater in smokers with normal pulmonary function tests (PFTs) but who have visual evid

233 Besides the global pulmonary function tests (PFTs) imaging techniques gaine

234 We sought to perform objective pulmonary function tests (PFTs) in HIV-infected and HEU

235 Pulmonary function tests (PFTs) that measured the diffus

236 Unfortunately many of them, for example pulmonary function tests (PFTs), clinical signs and conv

237 ging session followed by clinically standard pulmonary function tests (PFTs), the 6-minute walk test,

238 cluded time to death or worsening results of pulmonary function tests (PFTs).

239 nonobstructive pattern (FEV(1):VC >/=0.7) in pulmonary function tests 3 months after transplantation.

240 ho had undergone pre- and postbronchodilator pulmonary function tests and computed tomographic (CT) e

241 macular sub-layer thickness measurements and pulmonary function tests and disease duration.

242 Pulmonary function tests and time since symptom onset we

243 Among survivors with normal pulmonary function tests at t1, females and survivors tr

244 In addition, pulmonary function tests revealed stable vital capacity

245 tion and expiration, visual HRCT scores, and pulmonary function tests were obtained.

246 Bronchoalveolar lavage and pulmonary function tests were performed at intervals.

247 -terminal pro-brain natriuretic peptide, and pulmonary function tests were performed before (baseline

248 Pulmonary function tests were similarly obtained before

249 iagnosing BOS in patients with first drop of pulmonary function tests with a sensitivity of 96% and a

250 f inhaled corticosteroids were predictive of pulmonary function tests' outcome.

251 ictive lung pattern revealed by preoperative pulmonary function tests) and the transfusion (blood uni

252 All patients underwent pulmonary function tests, and measurement of fraction of

253 ic resonance imaging (MRI), echocardiograms, pulmonary function tests, and physical examinations.

254 Pulmonary function tests, Asthma Control Test (ACT), Ast

255 bjects and 30 patients with asthma underwent pulmonary function tests, blood and sputum eosinophil co

256 We analyzed pulmonary function tests, blood, and bronchoscopic biops

257 clinical history and examination, CD4 count, pulmonary function tests, Doppler echocardiography, and

258 tion computed tomography (HRCT) patterns and pulmonary function tests, including the composite physio

259 Exertional dyspnea disproportionate to pulmonary function tests, low carbon monoxide diffusion

260 h SA and its specific characteristics (i.e., pulmonary function tests, quality of life scores, urgent

261 ment of lung, cardiac, and sleep function by pulmonary function tests, transthoracic echocardiography

262 standardized interview, skin prick tests and pulmonary function tests.

263 need for a standardized reporting format for pulmonary function tests.

264 hickness, and body composition), asthma, and pulmonary function tests.

265 ee survival, modified Rodnan skin score, and pulmonary function tests.

266 ved in kidney angiomyolipoma size but not in pulmonary function tests.

267 nts were prospectively followed with routine pulmonary function tests.

268 ndings are more sensitive as compared to the pulmonary function tests.

269 ar retinal nerve fiber layer correlates with pulmonary function tests.

270 mptom-limited incremental cycle exercise and pulmonary functions tests (PFTs) and were compared with

271 pergillosis (ABPA) leads to deterioration of pulmonary function, the effect of A. fumigatus colonizat

272 fibrosis with mild-to-moderate impairment in pulmonary function to receive a three-drug regimen of pr

273 , we unraveled biologic processes underlying pulmonary function traits and identified a candidate gen

274 ostoperative period for patients with normal pulmonary function undergoing general anesthesia with en

275 We assessed pulmonary function using a peak flow meter to measure FV

276 tric measures, cardiometabolic risk factors, pulmonary function, vitamin status, gastrointestinal sym

277 Pulmonary function was assessed every year in a Mexican

278 emphysema and fibrosis extents and change in pulmonary function was assessed using multivariate linea

279 We tested the hypothesis that abnormal pulmonary function was associated with earlier death.

280 e association between marijuana exposure and pulmonary function was nonlinear (P < .001): at low leve

281 Vitamin D deficiency associated with pulmonary function was not statistically significant in

282 een eosinophil beta1-integrin activation and pulmonary function was replicated only for younger subje

283 In univariate analysis impaired pulmonary function was significantly associated with gre

284 Adverse events were recorded, pulmonary function was tested, and the modified Rodnan s

285 or demonstrated a significant improvement in pulmonary function, weight, and CFTR activity compared w

286 toperative long-term residual chest pain and pulmonary function were comparable in both groups.

287 Effects on pulmonary function were evident by 2 weeks, and a signif

288 and sputum cell differentials or measures of pulmonary function were examined by using partial least

289 ailure liver subscore equals to 3 but stable pulmonary function were identified and received either s

290 Specific airway resistance (SR(aw)) and pulmonary function were measured to determine the airway

291 Effects on pulmonary function were noted by 2 weeks, and a signific

292 of insulin resistance (HOMA-IR) and HDL, and pulmonary function were quantified in 168 adolescents, i

293 NHW in the COPDGene cohort, both measures of pulmonary function were significantly associated with SN

294 d microRNAs with inflammatory biomarkers and pulmonary function were tested with linear mixed effects

295 atients demonstrated a continuous decline in pulmonary function whereas the other had stable pulmonar

296 D025 resulted in normalization of pathogenic pulmonary function, which correlates with a marked reduc

297 han current or former smokers with preserved pulmonary function who were asymptomatic (CAT score, <10

298 inflammation with progression to compromised pulmonary function with age, reflecting the atopic march

299 also showed previously unexplored changes in pulmonary function, with AAV9-treated SOD1(G93A) mice di

300 iratory distress syndrome often recover full pulmonary function within six months.